School of Medicine

Researchers at Washington University School of Medicine are conducting an Alzheimer’s prevention trial with young adults from high-risk families to evaluate whether an investigational drug can clear a key Alzheimer’s protein, amyloid beta, and slow or stop the disease.

Thomas M. De Fer, MD, a nationally recognized leader in medical education, has been named director of the Division of General Medicine within the Department of Medicine at Washington University School of Medicine.

Roberto Galletto at the School of Medicine received a five-year $2.1 million MIRA grant from the National Institutes of Health (NIH).

Daniel Scott Marcus, professor of radiology at the School of Medicine, received a one-year $2 million grant from the National Institutes of Health (NIH).

Daniel Griffith, a predoctoral trainee in biochemistry at the School of Medicine, received a three-year $138,000 Graduate Research Fellowship award from the National Science Foundation.

Daniel Kerschensteiner, MD, professor of ophthalmology and visual sciences at the School of Medicine, received a five-year $2 million grant from the National Eye Institute of the National Institutes of Health (NIH) to study visual pathways.

Researchers at the School of Medicine were awarded $575.8 million in funding from the National Institutes of Health (NIH) in federal fiscal year 2021, according to the School of Medicine’s 2021 State of the School Report. This is an all-time high for the school.

Two research teams at Washington University — one led by Joyce Balls-Berry; the other led by Darrell Hudson and Ganesh Babulal — have received grants totaling $7 million to advance racial equity in Alzheimer’s disease research.

Samuel Achilefu, the Michel M Ter-Pogossian Professor of Radiology at the School of Medicine, received a four-year $2.2 million grant from the National Institute of Biomedical Imaging and Bioengineering of the National Institutes of Health (NIH) to research imaging techniques during surgery.

Researchers at Washington University School of Medicine have shown, in a small clinical trial, that pre-activated natural killer cells can help some children and young adults with recurrent acute myeloid leukemia and few other treatment options.